The Cancer Institute of New Jersey

Phoenix, Arizona 85032
cinjclinicaltrials@umdnj.edu

Use our guide to learn which trials are right for you!

Site Overview Research Experience Facility Info Investigator Experience Staff Experience Patient Demographics Therapeutic Areas

UMDNJ Clinical Research Organization

The Clinical Research Organization at the University of Medicine and Dentistry of New Jersey (UMDNJ) assembles the expertise, resources, intellect and motivation of faculty and staff across three medical schools and a dental school, six clinical research centers, and the technical and scientific capabilities of a state-wide institution to conduct clinical research in nearly all therapeutic areas. Each school and campus provides their own set of comprehensive research activities and is supported by a core of shared administrative competencies in human subjects' protections, financial management, legal management and technology transfer. The CRO provides a portal into the University to select services at specific sites, or concurrent services at multiple sites across the state; it matches internal capabilities with external constituents. A full description of our main biomedical research schools can be found at the following CenterWatch.com profiles:

  • New Jersey Dental School, Newark
  • New Jersey Medical School, Newark
  • Robert Wood Johnson Medical School, New Brunswick
    • Cancer Institute of New Jersey, New Brunswick
  • School of Osteopathic Medicine, Stratford

The UMDNJ CRO may be reached by contacting Ms. Debbie McCloskey, RN, BSN at CRO@umdnj.edu.

Cancer Institute of New Jersey

As New Jersey's first and only National Cancer Institute-designated Comprehensive Cancer Center, the Cancer Institute of New Jersey (CINJ) is dedicated to improving the prevention, detection, treatment, and care of patients with cancer through the transformation of laboratory discoveries into clinical practice. The coveted NCI designation, awarded to only 40 such centers nationwide, is granted competitively to institutions characterized by scientific excellence and the ability to bring research discoveries to patients.

CINJ delivers advanced comprehensive care for adults and children, conducts cutting-edge cancer research, transforms discoveries into clinical practice and provides education and outreach regarding cancer prevention, detection and treatment. CINJ manages more than 80,000 patient visits per year.

CINJ is comprised of a team of distinguished researchers and physicians who are internationally recognized in their field. CINJ's research and patient care tenets are based on multidisciplinary viewpoints and priorities to maintain the center's broad-based approach to cancer. Basic scientists, clinical researchers, and population scientists, who study cancer prevention and control, meet regularly to exchange information and ensure

  • laboratory discoveries are refined and applied to clinical care as quickly as possible;
  • clinical observations reach laboratory researchers on a continuing basis; and
  • prevention strategies are interwoven into all research programs.

CINJ organizes research and patient care along specific disease lines. Each disease area is assigned a focused, multidisciplinary team led by an academic physician who is an expert in the cause and treatment of that disease. A dedicated team of nationally renowned specialists including medical oncologists, surgical oncologists, radiation oncologists, social workers and nurses identify and meet the needs of each patient. CINJ's areas of care and research include:

Adult Oncology Programs:

  • Breast Oncology - Stacy Goldstein Breast Cancer Center
  • Gastrointestinal/Hepatobiliary Oncology Program
  • Genetic Counseling and Risk Assessment/The LIFE Center
  • Gynecologic Oncology Program
  • Leukemia/Lymphoma/Hematologic Malignancies
  • Liver Cancer and Bile Duct Cancer Care Program
  • Melanoma and Soft Tissue Oncology Program
  • Neuro-Oncology Program
  • Phase I/Developmental Therapeutics
  • Prostate Cancer: Dean and Betty Gallo Prostate Cancer Center
  • Radiation Oncology
  • Stem Cell Transplantation Program
  • Thoracic Oncology Program
  • Urologic Oncology Program

Pediatric Hematology/Oncology Program:

  • Pediatric Hemophilia Center
  • Comprehensive Sickle Cell Center
  • Bleeding Disorder Program
  • Pediatric Thrombosis Program
  • Neuro-oncology Program
  • Histiocytosis Program
  • Psychosocial Services
  • The Valerie Fund/CINJ LITE Program
  • Transitional Sickle Cell Program for Teens and Young Adults (jointly run by the UMDNJ-Robert Wood Johnson Medical School's Departments of Medicine and Pediatrics)

As the only NCI-designated cancer center in the state, CINJ's statewide network of 16 hospitals benefits from the clinical and research resources available only at CINJ. New treatments, discoveries and care standards are efficiently disseminated through the network, reaching patients and physicians close to their homes, through outreach, educational programs and collaborative efforts in clinical, basic, and cancer prevention research. Under the leadership of CINJ, physicians, nurses and researchers across New Jersey participate in the CINJ Oncology Group (CINJOG), which is able to address trends physicians may be seeing among their patient population through the development and implementation of new multi-center cancer clinical trials that will improve cancer treatments.

As a Center of Excellence of the UMDNJ' Robert Wood Johnson Medical School, CINJ is committed to learning more about cancer and availing to the public emerging discoveries which aid in disease prevention and improved treatments.

University of Medicine and Dentistry

UMDNJ, founded in 1970, has eight schools located throughout New Jersey. Our main campuses are Newark, Piscataway/New Brunswick, Stratford and Camden. Our campus collectively inhabits 185 acres, 64 buildings, 7.2 million square feet.

Our Schools include:

  • New Jersey Medical School
  • Robert Wood Johnson Medical School
  • School of Osteopathic Medicine
  • New Jersey Dental School
  • Graduate School of Biomedical Sciences
  • School of Health Related Professions
  • School of Nursing
  • School of Public Health

UMDNJ Clinical Research Organization:

  • The University Clinical Research Organization (CRO) offers a gateway for current and future patients and sponsors into campus-wide clinical trial activities.
  • The University CRO works with private sponsors to provide a single University-wide contact.
  • The University CRO works clinical trial units and research offices of each UMDNJ school to efficiently and effectively match trial and sponsor needs with University resources.

Our health care system includes:

  • 2.3 million patient visits to UMDNJ healthcare facilities and faculty practice offices last year.
  • Owns and operates UMDNJ-University Hospital (UH) in Newark with 22,192 admissions.
  • 221,371 outpatient visits last year.
  • Owns and operates University Behavioral HealthCare (UBHC), a state-wide behavioral health care provider.
  • 4 Principal Teaching hospitals (affiliated)
  • 3 University hospitals (affiliated)
  • Affiliations with more than 80 New Jersey hospitals and/or health systems.
  • More than 15 statewide centers of excellence
  • UMDNJ's clinical practices have off campus offices in 32 New Jersey communities.
  • UMDNJ has healthcare affiliates in each of New Jersey's 21 counties.

Due to its elevated NCI status, CINJ is able to provide access to clinical trials not available at other hospitals, clinics or doctor's offices. CINJ currently enrolls more than 1,000 patients in clinical trials, representing approximately 15 percent of all new adult CINJ cancer patients and approximately 70 percent of all pediatric cancer patients on clinical trials within the state. CINJ is committed to finding the latest and best treatment options for cancer patients through clinical trials.

The research base is organized into six programs: Cell Death and Survival Signaling, Genomic Instability and Tumor Progression, Cancer Pharmacology, Clinical Investigations, Carcinogenesis and Chemoprevention, and Quality and Outcomes in Cancer Care. CINJ has extensive experience conducting Phase I - IV trials in all therapeutic areas. Clinical trials in cancer prevention and cancer control span the following tumor groups:

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Leukemia
  • Lung
  • Lymphoma/Myeloma
  • Melanoma/Sarcoma
  • Pediatric
  • Prevention
  • Radiation
  • Phase I (not disease specific)

CINJ participates in many national Cooperative Group studies, including

  • Eastern Cooperative Oncology Group (ECOG)
  • Children's Oncology Group (COG)
  • National Surgical Adjuvant Breast and Bowel Project (NSABP).
  • Radiation Therapy Oncology Group (RTOG)
  • Southwest Oncology Group (SWOG)
  • Gynecologic Oncology Group (GOG)
  • Cancer and Leukemia Group B (CALGB)

To promote access to clinical trials, the CINJ Oncology Group (CINJOG) was developed from an association of referring physicians into a network of hospitals and community oncology practices that participate in investigator-initiated and cooperative oncology group studies to help bring clinical trials to communities throughout the entire state of New Jersey. This collaboration is helping find the answers to research questions more quickly by increasing the access to, and enrollment in clinical trials.

CINJOG enables patients to receive promising new treatments closer to home, without the burden of travel, and from a physician and healthcare team they already know. As new clinical trials are opened at CINJ, every effort is made to make sure the trial is available to local physicians in CINJOG practices across the state.

Our center has conducted research with the following modalities

  • Bone Marrow Transplant
  • Chemotherapy
  • Immunotherapy
  • Gene Therapy
  • Radiation Therapy
  • Surgery

As a major center for clinical trials and research, CINJ works with a variety of sponsoring companies and CRO's, as well as conducts many investigator-initiated protocols.

The school has significant experience in nearly all levels of clinical research in the full breadth of oncological therapeutic areas. As investigators and scientists, CINJ faculty are internationally known as prominent leaders in their respective fields. As physicians, they are motivated to improve not only the general health status of our state, country and world at large, but are also dedicated to applying the best medical care to each patient.

The clinical research staff has extensive experience in initiating and conducting clinical research projects of all phases and magnitudes. Their expertise includes, but is not limited to, study coordination, data and project management, human rights protection, patient safety and Good Clinical Practices, regulatory compliance, contracts and budgets, and coordinator support for new investigators. Our staff is well versed in acting as a central contact for sponsors and CROs.


We serve an economically and ethnically diverse patient population from the entire state of New Jersey, parts of Pennsylvania, New York and other states through-out the country.


Oncology

CINJ is located in New Brunswick, New Jersey. The caring environment that has been CINJ's hallmark from the beginning is evident throughout its facility. A special effort has been made to configure the patient care setting to create the feel of a much smaller institution - from the intimate clinical waiting rooms to the comfortable Resource and Learning Center, where patients and their families can review reliable, relevant and current information about all aspects of cancer. CINJ has statewide reach through its network of 16 hospitals.

CINJ's flagship hospital is Robert Wood Johnson University Hospital and CINJ's academic affiliate is The University Hospital/UMDNJ-New Jersey Medical School.

Major Clinical Research Affiliate Hospitals include Carol G. Simon Cancer Center at Morristown Memorial Hospital; Carol G. Simon Cancer Center at Overlook Hospital; Cooper University Hospital and Jersey Shore University Medical Center.

Affiliate Hospitals include Bayshore Community Hospital; CentraState Healthcare System; JFK Medical Center; Mountainside Hospital; Raritan Bay Medical Center; Robert Wood Johnson University Hospital at Hamilton (CINJ at Hamilton); Saint Peter's University Hospital; Somerset Medical Center; Southern Ocean County Hospital; and University Medical Center at Princeton.


Susan Goodin, PharmD BCOP
Associate Director
The Cancer Institute of New Jersey
Clinical Trials and Investigational Therapeutics
195 Little Albany & Somerset Street
New Brunswick, NJ
USA
cinjclinicaltrials@umdnj.edu


We've found
0 trials
at this facility